Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of PF-05251749 in Healthy Adults and Elderly
NCT02691702Phase 1Completed
- Sponsor
- Biogen
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-05251749 in Alzheimer's disease (AD) and Parkinson's disease (PD) (3 arms), sponsored by Biogen. Primary endpoints: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) - Alertness at Day 16, Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) - Calmness at Day 16 and 8 more. Started Mar 2016; status: completed.
02
Drugs
PF-05251749
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02691702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691702.